An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma

Published:2021-10-27 Issue:6 Volume:14 Page:2300-2313
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

De Meulenaere Astrid¹,Vermassen Tijl¹²³,Creytens David³⁴,De Keukeleire Stijn¹,Delahaye Tim⁵,Deron Philippe⁶,Duprez Fréderic⁷,Fung Samson⁵⁸,Pauwels Patrick⁹,Ferdinande Liesbeth³⁴,Rottey Sylvie¹²³

Affiliation:

1. Department of Medical Oncology University Hospital Ghent Ghent Belgium

2. Drug Research Unit Ghent University Hospital Ghent Ghent Belgium

3. Cancer Research Unit Ghent (CRIG) Ghent Belgium

4. Department of Pathology University Hospital Ghent Ghent Belgium

5. argenx B.V. Ghent Belgium

6. Department Of Head and Neck Surgery University Hospital Ghent Ghent Belgium

7. Department of Radiation Oncology University Hospital Ghent Ghent Belgium

8. Fung Consulting Healthcare and Life Sciences Eching Germany

9. Centre for Oncological Research (CORE) University of Antwerp, and University Hospital Antwerp Edegem Belgium

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13089

Reference33 articles.

1. Modern treatment for nasopharyngeal carcinoma: current status and prospects

2. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

3. Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival

4. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

5. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment;Journal of Translational Medicine;2024-04-18

2. Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells;British Journal of Pharmacology;2024-03-14

3. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers;Biomedicine & Pharmacotherapy;2024-02

4. The immune escape mechanism of nasopharyngeal carcinoma;The FASEB Journal;2023-06-26

5. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy;Haematologica;2023-02-09